Business Wire

Hexagon | AutonomouStuff Webinar Showcases How Velodyne’s Velarray H800 and PAEB Solution Can Power Advanced Driver Assistance Systems (ADAS) and Autonomy

8.12.2020 16:00:00 EET | Business Wire | Press release

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR) today announced Dr. Mircea Gradu, the company’s Senior Vice President of Product and Quality, is the featured speaker at a Hexagon | AutonomouStuff webinar on how lidar solutions can enhance safety in consumer vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005231/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Velodyne Lidar’s Velarray H800 solid state lidar sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. (Photo: Velodyne Lidar, Inc.)

The free webinar, called “Automotive-grade solid-state lidar for ADAS and autonomy: Velodyne Velarray H800,” takes place on December 15, 2020 at 2:00 p.m. EST. It is being moderated by Nicole Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff. To register, please click here.

The webinar will focus on the Velarray H800, Velodyne’s newly launched solid state lidar sensor designed for safe navigation and collision avoidance in advanced driver assistance systems (ADAS) and autonomous mobility applications. The Velarray H800 can help automakers design ADAS solutions that help reduce traffic accidents as well as injuries and deaths of drivers, passengers, bicyclists and pedestrians. The Velarray H800 is a key technology that will be used in systems for powerful vehicle safety, including for Automatic Emergency Braking, Lane Keep Assist and Adaptive Cruise Control.

The webinar will also cover Velodyne’s Pedestrian Automated Emergency Braking (PAEB) solution, which combines proprietary software, called Vella™, with Velodyne’s lidar sensors. Recent pedestrian crash statistics highlight an opportunity for PAEB systems to save thousands of lives annually by improving performance in dark conditions. According to the National Highway Traffic Safety Association, in 2018, 76% of the 6,283 total pedestrian crash fatalities in the U.S. occurred in dark conditions. Adding lidar can help address the risks that current PAEB systems present in frequently failing to protect pedestrians in dark conditions.

To demonstrate how PAEB systems can be achieved by utilizing lidar, Velodyne tested its lidar-based PAEB system against a highly-rated PAEB system built around camera and radar. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested. The combination of Velarray lidar data and Vella processing software dramatically improves PAEB performance, addressing a use case that causes thousands of pedestrian fatalities annually, and strengthening the vehicle’s functional safety achievements. For more information on the testing, please see Velodyne’s recently issued white paper regarding PAEB here.

“Lidar is an essential building block in creating advanced driving systems that improve vehicle, passenger and pedestrian safety. Webinar attendees can hear from a leading industry authority on how the Velarray H800 lidar sensor can help make cars and roadways safer for everyone,” said Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff.

“This webinar will discuss how automakers can significantly improve effectiveness and efficiency of vehicle driver-assist features and full autonomy by employing the Velarray H800. The sensor provides a revolutionary approach to making vehicles smarter and safer,” said Gradu.

Gradu leads Velodyne’s efforts to design, develop and manufacture world-class products compliant with international quality standards and is the 2018 President and Chairman of the Board of the Society of Automotive Engineers (SAE) International. He also is a Professor in the Mechanical and Aerospace Engineering Department at University of California Irvine (UCI), a member of UCI’s Institute for Transportation Studies Leadership Council and a FISITA Council member (International Federation of the Automotive Engineering Societies).

The Velarray H800 boasts outstanding range, field of view and resolution to support advancements in ADAS and autonomy, from Level 2 to Level 5. The sensor’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior. It is architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA).

About Velodyne Lidar

Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye